Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

David K. Simon; Tanya Simuni; Jordan Elm; Joanne Clark-Matott; Allison K. Graebner; Liana Baker; Susan R. Dunlop; Marina Emborg; Cornelia Kamp; John Christopher Morgan; G. Webster Ross; Saloni Sharma; Bernard Ravina

doi:10.3233/JPD-150666

Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

David K. Simon, Tanya Simuni, Jordan Elm, Joanne Clark-Matott, Allison K. Graebner, Liana Baker, Susan R. Dunlop, Marina Emborg, Cornelia Kamp, John Christopher Morgan, G. Webster Ross, Saloni Sharma, Bernard Ravina

Neurology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

Original language	English (US)
Pages (from-to)	731-736
Number of pages	6
Journal	Journal of Parkinson's Disease
Volume	5
Issue number	4
DOIs	https://doi.org/10.3233/JPD-150666
State	Published - Nov 21 2015

Keywords

8-hydroxydeoxyguanosine
8OHdG
IL-6
PGC-1alpha
Parkinsons disease
biomarker
cytokine
inflammation
interleukin-6
oxidativestress
pioglitazone

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.3233/JPD-150666

Cite this

@article{0df5589b8fd64368a8e7e5211325a30a,

title = "Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects",

abstract = "Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.",

keywords = "8-hydroxydeoxyguanosine, 8OHdG, IL-6, PGC-1alpha, Parkinsons disease, biomarker, cytokine, inflammation, interleukin-6, oxidativestress, pioglitazone",

author = "Simon, {David K.} and Tanya Simuni and Jordan Elm and Joanne Clark-Matott and Graebner, {Allison K.} and Liana Baker and Dunlop, {Susan R.} and Marina Emborg and Cornelia Kamp and Morgan, {John Christopher} and Ross, {G. Webster} and Saloni Sharma and Bernard Ravina",

year = "2015",

month = nov,

day = "21",

doi = "10.3233/JPD-150666",

language = "English (US)",

volume = "5",

pages = "731--736",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "IOS Press",

number = "4",

}

TY - JOUR

T1 - Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

AU - Simon, David K.

AU - Simuni, Tanya

AU - Elm, Jordan

AU - Clark-Matott, Joanne

AU - Graebner, Allison K.

AU - Baker, Liana

AU - Dunlop, Susan R.

AU - Emborg, Marina

AU - Kamp, Cornelia

AU - Morgan, John Christopher

AU - Ross, G. Webster

AU - Sharma, Saloni

AU - Ravina, Bernard

PY - 2015/11/21

Y1 - 2015/11/21

N2 - Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

AB - Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

KW - 8-hydroxydeoxyguanosine

KW - 8OHdG

KW - IL-6

KW - PGC-1alpha

KW - Parkinsons disease

KW - biomarker

KW - cytokine

KW - inflammation

KW - interleukin-6

KW - oxidativestress

KW - pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=84946603008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946603008&partnerID=8YFLogxK

U2 - 10.3233/JPD-150666

DO - 10.3233/JPD-150666

M3 - Article

C2 - 26444095

AN - SCOPUS:84946603008

SN - 1877-7171

VL - 5

SP - 731

EP - 736

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 4

ER -

Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this